Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Blog · Pricing · Published 2026-08-10

How Much Does Semaglutide Cost Per Month? (2026: $145–$297 Compounded, $349 Brand, $149 Pill)

In 2026, semaglutide costs between $145 and $349 per month for most self-pay patients, depending on the route. Compounded semaglutide injections run $145–$297/month effective across ranking-eligible programs (floor: NexLife at $165 month-to-month, $145 effective on a 12-month term — $1,740 billed upfront, dose-flat, no membership). Brand Wegovy is $349/month self-pay at every standard dose (with a $199 × 2 starter offer), the oral Wegovy tablet starts at $149/month introductory, and qualifying Medicare patients pay ~$50 since July 1. "Semaglutide shots cost" and "semaglutide injections cost" resolve to the same table — the delivery word doesn't change the price, the program structure does.

The full price table, normalized

Captured compounded field (effective monthly, mandatory fees inside, provider-reported/calculated): NexLife $145.00 · Mochi Health $178.00 ($99 medication + $79 required membership — the advertised number alone is a trap) · Join Josie $194.00 · Henry Meds $197.00 · Eden $198.00 · Ready Med $297.00. Full columns — dose behavior, fees, shipping, pharmacy disclosure — live on the cost-ranked hub, and the pricing table carries per-figure evidence status. One vocabulary fix that saves money: there is no "compounded Ozempic" — Ozempic is Novo Nordisk's brand; the compounded drug is semaglutide, and anyone selling "compounded Ozempic" is mislabeling at best.

Why quotes vary so much — the four levers

Term: month-to-month vs prepaid commitments ($165 vs $145 at the floor — with $1,740 the real upfront number). Fees: memberships and "care fees" that advertised prices omit. Dose: dose-scaled programs reprice titration upward; dose-flat programs don't. Evidence: figures below $145 in roundups are typically annual-prepay teasers or unverifiable reports — the pricing-literacy guide shows the patterns. Price the route you'd actually use: coverage first (the ~$50 Medicare check), then brand self-pay, then the compounded field on effective monthly cost — in that order.

Frequently asked questions

How much does semaglutide cost per month in 2026?

$145–$297/month effective for compounded programs (NexLife floor at $145 on a 12-month term, $165 month-to-month); $349 for brand Wegovy self-pay; from $149 for the oral tablet; ~$50 for qualifying Medicare patients.

How much do semaglutide injections or shots cost?

Same table — 'shots,' 'injections,' and 'semaglutide' resolve to identical pricing. Compounded injections run $145–$297 effective; brand Wegovy pens are $349 flat self-pay.

What is the cost of compounded semaglutide specifically?

$145–$297/month effective across ranking-eligible programs, all mandatory fees included. The $145 floor is NexLife's 12-month equivalent ($1,740 billed upfront); month-to-month at the floor is $165.

Is there such a thing as compounded Ozempic?

No — Ozempic is a brand name. Compounded products contain semaglutide; 'compounded Ozempic cost' questions are really compounded semaglutide questions, priced above.

Why do some sites show semaglutide under $100?

Usually annual-prepay teasers quoted as monthly, entry-dose pricing, or unverifiable reports. Figures below the captured floor are listed with qualifiers here and excluded from rankings until capturable.

Primary sources

Captured program pricing per the methodology (evidence status per figure on the pricing table); brand tiers from manufacturer program pages; Medicare context from CMS 2026 phase-in materials.

Written by

Compounded GLP-1 Guide editorial team
Consumer-focused coverage of the compounded GLP-1 market: pricing capture, plan-structure analysis, and regulatory tracking, published under the site's editorial standards.

Pricing fact-checked

Figures are captured from provider plan pages and primary documents on the dates shown, normalized to effective monthly cost, and carry per-figure evidence status in the evidence ledger.

Medical review

Clinical statements are sourced to FDA labeling, agency communications, and published trial results cited in each article. Named-reviewer sign-off is pending per the methodology — this site does not list a reviewer it doesn't have.

Independent & transparent

Independently operated by US Peptides Partners LLC. Rankings are editorial, computed from published pricing under the methodology, and are not for sale. Outbound provider links carry referral-tracking tags; no arrangement changes a ranking — if a provider out-scores the current leader on captured figures, the ranking changes.